Sunday’s Midday Stock Update: Teva Pharmaceutical Industries (TEVA), Recro Pharma (REPH), Glu Mobile (GLUU), Sangamo Biosciences (SGMO), Sarepta Therapeutics (SRPT)

So far Sunday, November 10, NASDAQ is up 1.9% and the S&P is up 1.14%. Here are this morning’s most active stocks: Teva Pharmaceutical Industries (TEVAResearch Report), Recro Pharma (REPHResearch Report), Glu Mobile (GLUUResearch Report), Sangamo Biosciences (SGMOResearch Report) and Sarepta Therapeutics (SRPTResearch Report).

Teva Pharmaceutical Industries is up 9.03% in midday trading to $9.30. Shares opened today at $8.53. The company has a 52-week low of $6.07 and a 52-week high of $24.47. On the Street’s front, the average 12-month analyst price target for the stock is $8.67, marking a 1.64% potential upside from current levels. In a report issued on November 8, Piper Jaffray analyst David Amsellem maintained a Hold rating on TEVA, with a price target of $7.00, which represents a potential downside of 18% from where the stock is currently trading. Separately, on October 22, Oppenheimer’s Esther Rajavelu reiterated a Buy rating on the stock and has a price target of $12.00. Over the last 3 months, the insider sentiment on Teva Pharmaceutical Industries has been negative based on 50 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Recro Pharma is up 6.73% in midday trading to $17.45. Shares opened today at $16.35. The company has a 52-week low of $5.53 and a 52-week high of $17.86. On the Street’s front, the average 12-month analyst price target for the stock is $19.50, marking a 19.27% potential upside from current levels. In a report issued on November 8, Oppenheimer analyst Leland Gershell maintained a Buy rating on REPH, with a price target of $22.00, which represents a potential upside of 35% from where the stock is currently trading.

Glu Mobile is up 6.02% in midday trading to $5.81. Shares opened today at $5.48. The company has a 52-week low of $4.11 and a 52-week high of $11.75. On the Street’s front, the average 12-month analyst price target for the stock is $7.29, marking a 33.03% potential upside from current levels. In a report issued on November 7, Wedbush analyst Michael Pachter reiterated a Buy rating on GLUU, with a price target of $7.50, which implies an upside of 37% from current levels. Separately, on August 19, Roth Capital’s Darren Aftahi maintained a Hold rating on the stock and has a price target of $7.00. Over the last 3 months, the insider sentiment on Glu Mobile has been negative based on 40 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Sangamo Biosciences is up 5.91% in midday trading to $9.85. Shares opened today at $9.30. The company has a 52-week low of $6.26 and a 52-week high of $13.91. On the Street’s front, the average 12-month analyst price target for the stock is $13.50, marking a 45.16% potential upside from current levels. In a report issued on November 7, Cowen analyst Ritu Baral maintained a Buy rating on SGMO. Separately, on August 12, Wedbush’s Liana Moussatos reiterated a Hold rating on the stock and has a price target of $11.00.

Sarepta Therapeutics is up 5.8% in midday trading to $96.28. Shares opened today at $91.00. The company has a 52-week low of $72.05 and a 52-week high of $158.80. On the Street’s front, the average 12-month analyst price target for the stock is $191.19, marking a 110.10% potential upside from current levels. In a report issued on November 8, RBC analyst Brian Abrahams maintained a Buy rating on SRPT, with a price target of $200.00, which implies an upside of 120% from current levels. Separately, on October 8, Oppenheimer’s Hartaj Singh maintained a Hold rating on the stock . Over the last 3 months, the insider sentiment on Sarepta Therapeutics has been positive based on 33 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.